The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $1.96 in the prior trading day, Dare Bioscience Inc (NASDAQ: DARE) closed at $1.93, down -1.53%. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 0.16 million shares were traded. DARE stock price reached its highest trading level at $1.9802 during the session, while it also had its lowest trading level at $1.9.
Ratios:
Our goal is to gain a better understanding of DARE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.18 and its Current Ratio is at 1.18. In the meantime, Its Debt-to-Equity ratio is 2.85 whereas as Long-Term Debt/Eq ratio is at 1.98.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DARE now has a Market Capitalization of 26015438 and an Enterprise Value of 7435497. Its current Enterprise Value per Revenue stands at -130.15 whereas that against EBITDA is -0.454.
Stock Price History:
The Beta on a monthly basis for DARE is 0.79, which has changed by -0.39130437 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, DARE has reached a high of $9.19, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is -1.19%, while the 200-Day Moving Average is calculated to be -19.88%.
Shares Statistics:
The stock has traded on average 199.04K shares per day over the past 3-months and 209150 shares per day over the last 10 days, according to various share statistics. A total of 13.93M shares are outstanding, with a floating share count of 13.08M. Insiders hold about 8.47% of the company’s shares, while institutions hold 7.06% stake in the company. Shares short for DARE as of 1765756800 were 466123 with a Short Ratio of 2.34, compared to 1763078400 on 241155. Therefore, it implies a Short% of Shares Outstanding of 466123 and a Short% of Float of 3.2899998.
Earnings Estimates
A comprehensive evaluation of Dare Bioscience Inc (DARE) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.46. Analysts are recommending an EPS of between -$1.48 and -$1.86 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$0.35, with 3.0 analysts recommending between $1.23 and -$1.69.
Revenue Estimates
2 analysts predict $765k in revenue for . The current quarter. It ranges from a high estimate of $1.43M to a low estimate of $103k. As of . The current estimate, Dare Bioscience Inc’s year-ago sales were -$63.65kFor the next quarter, 2 analysts are estimating revenue of $1.57M. There is a high estimate of $2.9M for the next quarter, whereas the lowest estimate is $250k.
A total of 2 analysts have provided revenue estimates for DARE’s current fiscal year. The highest revenue estimate was $1.43M, while the lowest revenue estimate was $109k, resulting in an average revenue estimate of $771k. In the same quarter a year ago, actual revenue was $9.78kBased on 3 analysts’ estimates, the company’s revenue will be $22.55M in the next fiscal year. The high estimate is $56.58M and the low estimate is $1.09M.
